Balancing Treatment Intensity, Quality of Life, and Biomarker-Driven Approaches in Advanced GI Cancers
Panelists discuss how balancing treatment intensity with quality of life remains a critical challenge in advanced gastric cancers (GCs) and how implementing biomarker-driven approaches such as PD-L1 combined positive score (CPS) testing faces practical hurdles in clinical settings. Key considerations include optimizing patient outcomes while managing adverse effects and addressing barriers such as testing accessibility, result turnaround time, and standardization of biomarker interpretation.
- How might these findings shape discussions about the balance between treatment intensity and maintaining patients’ quality of life in advanced GC/gastroesophageal junction cancer/esophageal adenocarcinoma?
- What barriers might exist in applying biomarker-driven approaches, such as PD-L1 CPS, in real-world clinical settings, and how can they be addressed?
FDA Approves Pembrolizumab/Chemo in First-Line Gastric/GEJ Adenocarcinoma
March 19th 2025Data from the phase 3 KEYNOTE-811 trial supported the FDA approval of this pembrolizumab combination in locally advanced unresectable or metastatic, PD-L1–positive, HER2-positive gastric or GEJ adenocarcinoma.
